145 related articles for article (PubMed ID: 32911987)
1. Sclerosing Extramedullary Hematopoietic Tumor: A Case Report.
Wang D; Castro E; Rao A; McPhaul CM
J Investig Med High Impact Case Rep; 2020; 8():2324709620956463. PubMed ID: 32911987
[TBL] [Abstract][Full Text] [Related]
2. JAK2-positive cutaneous myelofibrosis presenting as sclerosing extramedullary hematopoietic tumors on the scalp: case presentation and review of the literature.
LeBlanc RE; Lester L; Kwong B; Rieger KE
J Cutan Pathol; 2015 Nov; 42(11):858-62. PubMed ID: 26153565
[TBL] [Abstract][Full Text] [Related]
3. Sclerosing extramedullary hematopoietic tumor: emphasis on diagnosis by renal biopsy.
Sukov WR; Remstein ED; Nascimento AG; Sethi S; Lewin M
Ann Diagn Pathol; 2009 Apr; 13(2):127-31. PubMed ID: 19302963
[TBL] [Abstract][Full Text] [Related]
4. Sclerosing extramedullary hematopoietic tumor in chronic myeloproliferative disorders.
Remstein ED; Kurtin PJ; Nascimento AG
Am J Surg Pathol; 2000 Jan; 24(1):51-5. PubMed ID: 10632487
[TBL] [Abstract][Full Text] [Related]
5. Sclerosing extramedullary hematopoietic tumor presenting as an inguinal mass in a patient with primary myelofibrosis: a diagnostic pitfall.
Gu MJ
Int J Clin Exp Pathol; 2015; 8(3):3381-3. PubMed ID: 26045874
[TBL] [Abstract][Full Text] [Related]
6. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous myelofibrosis with JAK2 V617F mutation: metastasis, not merely extramedullary hematopoiesis!
Fraga GR; Caughron SK
Am J Dermatopathol; 2010 Oct; 32(7):727-30. PubMed ID: 20859081
[TBL] [Abstract][Full Text] [Related]
8. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Palova M; Szotkowski T; Hlusi A; Indrak K; Navratilova J; Divoka M; Papajik T
Neoplasma; 2018; 65(2):296-303. PubMed ID: 29534592
[TBL] [Abstract][Full Text] [Related]
9. Postsplenectomy sclerosing extramedullary hematopoietic tumor with unexpected good clinical evolution: morphologic, immunohistochemical, and molecular analysis of one case and review of the literature.
Gualco G; Ojopi EB; Chioato L; Cordeiro DL; Negretti F; Bacchi CE
Appl Immunohistochem Mol Morphol; 2010 May; 18(3):291-5. PubMed ID: 20042850
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
11. CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms.
Nomani L; Bodo J; Zhao X; Durkin L; Loghavi S; Hsi ED
Am J Clin Pathol; 2016 Oct; 146(4):431-8. PubMed ID: 27686170
[TBL] [Abstract][Full Text] [Related]
12. Intracranial sclerosing extramedullary haematopoietic tumour mimicking meningioma in a patient with myelofibrosis: Case report.
Woodward Z; Robertson T; Sim S; Tollesson G
J Clin Neurosci; 2021 Jun; 88():268-270. PubMed ID: 33992195
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
14. Frequency and molecular characteristics of calreticulin gene (CALR) mutations in patients with JAK2 -negative myeloproliferative neoplasms.
Wojtaszewska M; Iwoła M; Lewandowski K
Acta Haematol; 2015; 133(2):193-8. PubMed ID: 25323779
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic myelofibrosis with nodal, serosal and parenchymatous infiltration. Case report and review of the literature.
Tzankov A; Krugmann J; Steurer M; Dirnhofer S
Acta Haematol; 2002; 107(3):173-6. PubMed ID: 11978939
[TBL] [Abstract][Full Text] [Related]
17. Sclerosing extramedullary hematopoietic tumor.
Yang X; Bhuiya T; Esposito M
Ann Diagn Pathol; 2002 Jun; 6(3):183-7. PubMed ID: 12089730
[TBL] [Abstract][Full Text] [Related]
18. Extramedullary hematopoiesis in an inguinal lymph node: an unusual presentation of primary myelofibrosis.
Yaqoob N; Mansoor N; Naveed H; Jamal S
World J Surg Oncol; 2022 Jun; 20(1):186. PubMed ID: 35676715
[TBL] [Abstract][Full Text] [Related]
19. Hmga2 promotes the development of myelofibrosis in Jak2
Dutta A; Hutchison RE; Mohi G
Blood; 2017 Aug; 130(7):920-932. PubMed ID: 28637665
[TBL] [Abstract][Full Text] [Related]
20. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
